BNB treasury firm plunges 77% after Nasdaq delisting notice

Biotech and BNB treasury firm Windtree Therapeutics fell 77% on Wednesday after informing the SEC that it would be delisted from the Nasdaq stock exchange.

Windtree Therapeutics, a biotech company that established a BNB treasury strategy last month, fell 77% on Wednesday after the Nasdaq informed the firm it would be delisted from the stock exchange for failing to meet compliance requirements.

The noncompliance concerned Nasdaq Listing Rule 5550(a)(2) that requires a company’s stock to maintain a minimum bid price of $1.00 per share, Windtree stated in a filing to the US securities regulator on Tuesday. Nasdaq will suspend WINT trading on Thursday. 

Windtree (WINT) shares dropped a staggering 77.2% to $0.11 on the news, and are down another 4.7% in after-hours, Google Finance data shows. WINT shares saw a minor rise on July 16, when it announced its BNB treasury strategy, but have fallen over 90% since its July 18 peak.

Read more

Subscribe for The Latest Crypto News and deals.

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

World Wide Crypto will use the information you provide on this form to be in touch with you and to provide updates and marketing.